These have grown faster than even monoclonal and multi-specific antibodies. Our research shows that ADCs will change the standard of care in oncology across the board. The recent deal between ...

UK biotech company Kymab is to collaborate with China’s EpimAb Biotherapeutics to develop bispecific antibodies in the immuno-oncology field. Kymab has developed a next-generation antibody ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...